Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review by Nyrop, K.A. et al.
Weight changes in postmenopausal breast cancer survivors
over 2 years of endocrine therapy: a retrospective chart review
Kirsten A. Nyrop1,5 • Allison M. Deal1 • Jordan T. Lee2 • Hyman B. Muss1,5 •
Seul Ki Choi3 • Samara Dixon1 • Amy Wheless1 • Lisa A. Carey1,5 •
Shlomit S. Shachar4
Received: 28 October 2016 /Accepted: 6 January 2017 / Published online: 2 February 2017
Abstract
Purpose Obesity and weight gain after breast cancer (BC)
diagnosis can affect cancer outcomes. This study explores
the question of weight change during the first 2 years of
endocrine treatment (ET) to identify the independent effects
of BC diagnosis and treatment on post-diagnosis weight
trajectories in early-stage postmenopausal BC survivors.
Methods The study design is a retrospective chart review.
Chi square tests and ANOVAwere used to compare patients
who gained[2 kg, lost[2 kg, or had stable weight. Log-
binomial regression models were used to evaluate associa-
tions between patient characteristics and weight trajectories.
Results The final sample is N = 300, with mean age at BC
diagnosis of 65 years and 76% white. After 2 years of ET,
39% of study participants had gained[2 kg, 27% had lost
[2 kg, and 34% had stable weight. Relative risks (RR) for
weight gain were as follows: age at diagnosis = 0.98 (0.96,
0.99), being married = 1.48 (1.04, 2.12), weight change
between BC diagnosis and start of ET = 0.98 (0.97, 0.99),
Stage II = 1.42 (1.01, 2.01) or Stage III = 1.99 (1.41,
2.82), PR negative = 0.70 (0.51, 0.96), HER2 posi-
tive = 1.51 (1.07, 2.13), mastectomy = 1.49 (1.12, 1.98),
axillary node dissection = 1.67 (1.27, 2.20), adjuvant
chemotherapy = 1.49 (1.02, 2.19), and neoadjuvant
chemotherapy = 2.29 (1.67, 3.14). Type of ET (tamoxifen
or aromatase inhibitor) was not significant.
Conclusions In our sample of postmenopausal early-stage
BC survivors, a majority had stable or lost weight during
the first 2 years of ET. Higher disease complexity and
associated treatment posed higher RR for weight gain.
Keywords Early stage breast cancer  Postmenopausal 
Weight trajectories  Endocrine treatment  Chemotherapy
Introduction
Obesity, body composition, and energy balance have
emerged as central concerns in cancer risk, prognosis, and
survivorship [1–5], and as high priorities in oncology
research [6–8]. This concern is reflected in clinical practice
guidelines that emphasize attention to weight and energy
balance through physical activity in cancer care [2, 4, 9–11].
In breast cancer (BC), a majority of women are overweight
or obese at diagnosis [12, 13], with evidence linking risk for
BC diagnosis with above normal weight especially strong in
postmenopausal women [14–19].
Implications of weight gain after BC diagnosis
In addition to being a risk factor for BC, obesity at BC
diagnosis and weight gain after diagnosis have implications
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survivors has also been associated with intensified hot
flashes [49, 50], physical function limitations [51], and
other strains on quality of life [52]. For all of these reasons,
the potential for weight gain during or associated with ET
is of concern to both BC survivors who are about to start
ET and to their oncology providers.
Need for further research
To identify the independent association of ET with weight
gain and potential risk factors for weight gain during ET,
our research team reviewed the literature from randomized
controlled efficacy trials of ETs as well as observational
studies of weight or weight change in BC survivors [53].
Specifically with regard to postmenopausal women, we
found that proportions reporting weight gain as a ‘‘symp-
tom’’ or bothersome symptom’’ ranged widely from 18 to
44% in Year 1 [54, 55] and from 7 to 55% in Year 5
[56, 57]. Among studies where weight in general and
weight change over time were independently assessed by
clinical or research staff, one study reported[5 kg weight
gain in 42% of women after 5 years on ET [58]. There was
so much variation in the proportions of BC survivors who
gained weight and in the amount of weight gain that it was
not possible to ascertain definitive trends from the current
evidence. Research gaps included specific and consistent
timeframes (e.g., from BC diagnosis to a specific year of
ET, or from start of ET to a specific year of ET), specific
amounts of weight change (kilograms or pounds), and
proportions who gained, lost, or remained stable (not just
the proportion who gained or reported weight gain).
Current study
In light of the inconclusive evidence and to further explore
the question of weight gain in postmenopausal BC sur-
vivors on ET, we report here findings from a retrospective
chart review focused on weight change during the first
2 years of ET. We focus on this timeframe because this is
usually a period when BC survivors have regularly
scheduled clinic visits with their oncology provider in
order to monitor disease recurrence and ET side effects,
including significant weight changes. Our specific focus is
independently assessed weight measures (kg) that are
routinely taken by clinic staff during these visits, because
these measures are readily accessible for oncology provi-
ders interested in monitoring weight changes in their
patients. The first aim of our study is to describe weight
trajectories in this patient population, with weight catego-
rized as C2 kg weight gain, C2 kg loss, or stable weight
(within 2 kg). Our second aim is to describe BC tumor and
treatment factors associated with weight change during the
first 2 years of ET, with the specific objective of
for prognosis, survival, and quality of life, again with 
evidence of adverse outcomes strongest in postmenopausal 
women. For example, high body mass index (BMI) at 
diagnosis has been associated with increased risk for BC 
mortality, with one study attributing 30–50% of BC deaths 
among postmenopausal women to high BMI at diagnosis 
[20]. Further, in a pooled analysis of 5675 estrogen 
receptor-positive BC survivors, 73% of whom were post-
menopausal, the hazard ratio for late recurrence (C5 years)
was significant for women who experienced [10% pre- to 
post-diagnosis weight change (HR 1.24, 95% CI 
1.00–1.53); it was also significant for BMI in the range of
30 to \35 at 2 years of post-diagnosis (HR 1.40, 95% CI 
1.05–1.86) [21]. In another study, where 68% of the 
women were postmenopausal at BC diagnosis, survivors
who gained [10% after diagnosis had worse all-cause 
mortality (HR 2.67, 95% CI 1.37–5.05) compared to 
women who maintained their pre-diagnosis weight (plus or 
minus 5% weight change), with a trend towards higher 
mortality when weight gain occurred within the first 
2 years of diagnosis (HR 5.87, 95% CI 0.87–47.8) as 
compared to later (HR 1.49, 95% CI 0.85–2.57) [22]. That 
study also found that [10% weight gain after diagnosis 
was associated with worse BC-specific mortality (HR 2.84, 
95% CI 1.15–6.65) [22]. A meta-analysis of post-
menopausal BC survivors found a 15% increased risk for 
overall mortality (HR 1.15, 95% CI 1.06–1.26) and 38%
increased risk for BC-specific mortality (HR 1.38, 95% CI 
1.11–1.71) in obese as compared to non-obese BC sur-
vivors [23].
The role of endocrine treatment in weight gain
in postmenopausal breast cancer survivors
Receipt of chemotherapy has been linked to weight gain 
since the 1970s in both pre- and postmenopausal survivors 
[24–26]. The question arises whether other BC treatments 
are associated with weight gain. In postmenopausal 
women, most BC tumors (60–80%) are hormone receptor 
(HR)-positive [27–32] and discovered at an early, highly 
curable stage [33, 34]. For postmenopausal women with 
this diagnosis, clinical guidelines recommend that adjuvant 
therapy includes endocrine treatment (ET) for at least 
5 years to dramatically improve their overall prognosis and 
survival [35–38]. ET options are an aromatase inhibitor 
(AI) (anastrozole, letrozole, or exemestane) or selective 
estrogen receptor moderator (tamoxifen). For women on an 
AI, weight gain is of particular concern because it may 
exacerbate the common side effect of AI-associated 
arthralgia (joint pain, stiffness, or achiness) [39]. Weight 
gain may also be factor in ET treatment discontinuation 
[40–43] and may affect the efficacy of AI therapy [44–48]. 
Post-diagnosis weight gain in postmenopausal BC
identifying the independent effect of each ET and of
chemotherapy.
Methods
Data were derived from clinician notes and other medical
personnel entries (such as nursing staffing assessed height
and weight, and technician notes regarding chemotherapy
and radiation) in the electronic medical records (EMR) of
women seen in BC clinics of a university-affiliated ter-
tiary hospital. To ensure best practice in retrospective
chart review [59], the following procedures were fol-
lowed: (1) research questions were well defined and
clearly articulated a priori; (2) all variables used in our
analysis had the same purpose as their original clinical
intent (such as describing the BC diagnosis and treat-
ment); (3) a standardized data abstraction form was used;
(4) the abstractor was trained and monitored; (4) ambi-
guities in the data were resolved through discussion and
consensus; (5) explicit inclusion and exclusion criteria
were developed at the onset; and (6) confidentiality and
ethical consideration were reviewed and approved by the
Institutional Review Board of the University of North
Carolina at Chapel Hill (IRB 15-1523).
Study participants
Female BC patients were identified on a consecutive basis
from clinic schedules and from the Neoadjuvant Database
at the University of North Carolina (UNC) Lineberger
Comprehensive Cancer Center (LCCC9815, IRB 01-1154).
To eliminate the known association of menopausal status
with weight gain in BC survivors [60, 61], we limited our
study to women who were postmenopausal at the time of
their first BC diagnosis. Postmenopausal status was recor-
ded in the clinician notes when a treatment plan that
includes ET was presented to the patient and/or when ini-
tiation of ET was discussed with the patient. Clinicians
state the patient’s menopausal status as the reason for
prescribing a specific ET, such as AI rather than tamoxifen,
and sometimes also refer to lab tests to confirm menopausal
status. BC survivors also had to meet the following eligi-
bility criteria: stage 0-III BC diagnosis, on ET for at least
2 years, and weight data throughout 2 years of ET.
Women were excluded if their BC had recurred or
metastasized within the timeframe of our study (BC diag-
nosis through 2 years of ET), as disease progression could
have an independent effect on weight change (e.g., weight
loss) [62]. BC survivors were also excluded if they had
other non-cancer comorbidities described in clinician notes
as poorly controlled or mobility impairments (such as
being wheelchair bound) as these circumstances may have
an independent effect on weight trajectories [63, 64].
Finally, women were excluded when clinician notes doc-
umented ET non-adherence or discontinuation, as ET dose
may affect weight trajectories. Individual cases of inclusion
or exclusion from the study were discussed and determined
jointly by three authors (KAN, SSS, and JTL).
Measures
Variables selected for inclusion in the study were deter-
mined for their hypothesized potential association with
weight trajectories and the quality and consistency of their
availability in the EMR. All data were extracted from
clinician notes with the exception of weight data which
were recorded in the EMR by nursing staff. Data from the
EMR were entered into a REDCap [65] database and
included the following: (a) patient-reported age, race,
ethnicity, marital status, and employment status at BC
diagnosis; (b) BC diagnosis (stage, grade, nodal status,
hormone receptor (HR) status, HER2 status); (c) BC
treatment (surgery type, axillary surgery, chemotherapy,
radiation); (d) ET history (including switching among
ETs); (e) history of hormone replacement therapy (HRT);
and (f) comorbidities at BC diagnosis. Height and weight
were independently assessed by BC clinical staff at the
time of diagnosis and at 3–4 month intervals for the first
2 years of ET, using scales located in the BC clinic and
standardized procedures for measuring height and weight.
The final weight measure was within 3 months of com-
pleting 2 years on ET. Data entry was conducted by one
author (JTL) with training and quality control provided by
three authors (AMD, SSS, and KAN). Completeness and
accuracy of the data were achieved through cross-checking
within the patient’s medical record to resolve any incon-
sistencies in clinician entries.
Statistical analysis
Descriptive statistics were used to characterize the final
sample and summarize findings based on three weight
change classifications from the first 2 years on ET: weight
loss[2 kg, stable weight plus or minus 2 kg, and weight
gain [2 kg. Among 300 participants, 38 had 24-month
weight data imputed from weight data at 21 months. Per-
centages and means are compared between patients in the
three weight change groups using Chi squared tests and
ANOVA. Log-binomial regression models are used to
evaluate univariate associations between patient charac-
teristics and weight gain of more than 2 kg, and relative
risks (RR) are reported for all variables. All analyses were
conducted using SAS v9.4 statistical software (Cary, NC).
Results
Study participant characteristics
Characteristics of the final sample (N = 300) are presented
in Table 1 (see Fig. 3 in Appendix for a flow diagram of
BC survivors excluded from the final sample). Mean age at
BC diagnosis was 65 years and the sample was predomi-
nantly white (76%), non-Hispanic (98%), married (64%),
and currently not employed (55%). At the time of BC
diagnosis, the mean BMI was 29, with most participants
categorized as overweight (28%) or obese (39%). None of
the study participants were below normal weight at
diagnosis. Mean number of comorbidities at BC diagnosis
was 2.2, ranging from 0 to 6. Eighty-two percent of tumors
were Stage 0–II and 71% were Grade 1 or 2. BC surgery
was 57% lumpectomy and 43% mastectomy. Most axillary
surgery was axillary dissection (67%). Forty-nine percent
of study participants had chemotherapy and 68% had
radiation. ET treatments were 38% anastrozole, 19%
letrozole, 3% exemestane, 14% tamoxifen, 13% more than
one AI, and 13% tamoxifen and AI. Mean time from BC
diagnosis to start of ET was 0.46 years (SD 0.46), 0.26 (SD
0.21) for women who did not receive chemotherapy, and
0.66 years (SD 0.31) for those who received
chemotherapy.
Table 1 Study participant
characteristics (N = 300)
Variable Results
Mean (standard deviation) or %
At diagnosis
Age 64.4 (SD 8.6) (range 42.6–92.0)
Race
White 76




Not married (single, separated, divorced, widowed) 36
Employment status
Currently not employed 55
Currently employed 45
Body mass index (BMI) category 29.3 (SD 6.7) (range 18.6–58.6)
Normal (18.5 to\25) 33
Overweight (25 to\30) 28
Obese I (30 to\35) 21
Obese II (C35) 18
Hormone replacement therapy 57

















Weight change during first 2 years of ET
Associations between participant characteristics and weight
change are presented in Table 2, with study participants
grouped into one of the three categories according to their
weight change at the end of 2 years on ET. Overall, 39% of
study participants gained[2 kg, 27% lost C2 kg, and 34%
had stable weight (±2 kg). Weight gain and weight loss
proportions in 2 kg increments are shown in Fig. 1. Fig-
ure 2 shows that women who were overweight (BMI
25–29.9) or obese class I (BMI 30–34.9) at BC diagnosis
had the highest proportion of women who gained [2 kg
during ET, with more than 40% of the women in these two
groups gaining [2 kg. In turn, women who were obese
class II (BMI C 35) at BC diagnosis comprised the highest
proportion of women who lost[2 kg (46%) during 2 years
of ET, and women who were normal weight at BC diag-
nosis had the highest proportion whose weight remained
stable during ET (44%). Patient characteristics significantly
associated with weight gain in 2 years of ET were as fol-
lows: being married (p = 0.05), weight loss between
diagnosis and start of ET (p\ 0.01), BMI category at
diagnosis (p\ 0.01), higher tumor stage (p\ 0.01),
HER2-positive tumor (p = 0.03), mastectomy (p\ 0.01),
axillary node dissection (p\ 0.01), and chemotherapy
(p\ 0.01).
Unadjusted relative risk for weight gain
In Table 3, we present the RR for gaining more than 2 kg
during ET based on participant characteristics. Significant
differences in risk (95% confidence interval) were found
for being married RR = 1.48 (1.04, 2.12) (p = 0.03),
Stage II RR = 1.42 (1.01, 2.01) (p = 0.04) or III
RR = 1.99 (1.41, 2.82) (p = 0.0001), HER2-positive
RR = 1.51 (1.07, 2.13) (p = 0.02), mastectomy
RR = 1.49 (1.12, 1.98) (p = 0.006), axillary node dissec-
tion RR = 1.67 (1.27, 2.20) (p = 0.0002), adjuvant
chemotherapy RR = 1.49 (1.02, 2.19) (p = 0.04), and
neoadjuvant chemotherapy RR = 2.29 (1.67, 3.14)
(p\ 0.0001). Older women had a lower risk for weight
gain during ET RR = 0.98 (0.96, 0.99) (p = 0.002), as did
women with Progesterone Receptor (PR)-positive tumors’
RR = 0.70 (0.51, 0.96) (p = 0.03). Weight loss between
Table 1 continued
Variable Results



















Anastrozole only (Arimidex) 38
Letrozole only (Femara) 19
Exemestane only (Aromasin) 3
Tamoxifen only 14
More than one AI 13
Tamoxifen and AI 13
ET endocrine treatment, ER estrogen receptor, PR progesterone receptor, HER 2 human epidermal growth
factor receptor 2, AI aromatase inhibitor
Table 2 Associations between participant characteristics and weight change after 2 years on endocrine treatment (ET) (N = 300)
Weight status after 2 years on endocrine treatment (ET) p value
[2 kg weight loss
(N = 81, 27%)
Stable weight
(N = 102, 34%)
[2 kg weight gain
(N = 117, 39%)








Other (N = 73) 33% 36% 32% 0.26
White (N = 227) 25% 34% 41%
Marital status
Other (N = 95) 35% 36% 30% 0.05
Married (N = 167) 24% 32% 44%
Currently employed
No (N = 136) 27% 32% 41% 0.99
Yes (N = 11) 28% 32% 40%
BMI category at diagnosis
Normal (18.5 to\25) (N = 94) 21% 44% 35% <0.01
Overweight (25 to\30) (N = 80) 29% 28% 43%
Obese I (30 to\35) (N = 59) 19% 39% 42%
Obese II (C35) (N = 52) 46% 15% 39%












Range -19.9 to 6.5
<0.01
Hormone replacement therapy
Yes (N = 117) 26% 37% 38% 0.94
No (N = 89) 28% 36% 36%






0–1 comorbidities (N = 103) 23% 38% 39% 0.49
2–3 comorbidities (N = 138) 26% 34% 40%
C4 comorbidities (N = 59) 36% 27% 37%
Stage
Stage 0 (N = 5) 60% 20% 20% <0.01
Stage I (N = 127) 36% 34% 30%
Stage II (N = 108) 24% 33% 43%
Stage III (N = 52) 10% 31% 60%
Grade
1 (N = 77) 35% 30% 35% 0.27
2 (N = 124) 28% 33% 39%
3 (N = 83) 19% 39% 42%
Estrogen receptor
Positive (N = 294) 28% 34% 39% 0.38
Negative (N = 5) 0% 60% 40%
Progesterone receptor
Positive (N = 248) 27% 36% 36% 0.07
Negative (N = 48) 27% 21% 52%
HER2
Positive (N = 35) 30% 34% 36% 0.03
Negative (N = 250) 11% 34% 54%
BC diagnosis and start of ET was associated with weight
gain during ET RR = 0.98 (0.97, 0.99) (p\ 0.0001). No
significant differences based on ET were observed.
Adjusted relative risk for weight gain
To avoid multicollinearity among multiple measures for BC
tumor severity (stage, PR, HER2) and treatment (breast sur-
gery, node surgery, chemotherapy), we ran separate multi-
variable models of each treatment type adjusted for BC stage:
In the surgery model, mastectomy RR = 1.30 (0.96, 1.75)
(p = 0.09) and stage RR = 1.32 (1.10, 1.59) (p = 0.002); In
the node surgery model, axillary node dissection RR = 1.36
(0.97, 1.91) (p = 0.08) and stage RR = 1.24 (1.00, 1.54)
(p = 0.05); In the chemotherapy model, adjuvant
chemotherapy RR = 1.35 (0.90, 2.03) (p = 0.15), neoadju-
vant chemotherapy RR = 1.95 (1.29, 2.93) (p = 0.002), and
stage RR = 1.12 (0.91, 1.39) (p = 0.29).
Sub-analysis of weight loss prior to ET
Weight loss between BC diagnosis and start of ET was
associated with [2 kg weight gain during ET. To
investigate this further, we conducted a sub-analysis to
evaluate which patient characteristics were associated with
losing[2 kg prior to ET. Patients with higher BC stage (22
vs 32 vs 47%, p\ 0.01), increasing tumor grade (20 vs 30
vs 39%, p = 0.05), who received mastectomy (37 vs 25%,
p = 0.04), axillary node dissection (42 vs 25%, p\ 0.01),
and chemotherapy (43 vs 17%, p\ 0.0001), were all sig-
nificantly more likely to lose[2 kg prior to ET.
Discussion
We conducted a retrospective cohort study to investigate a
question of concern to both BC survivors and their
oncology providers: is weight gain associated with taking
ET in early-stage BC. The weight data evaluated in our
study were routinely collected by nursing staff during
clinic visits in the first 2 years of ET. We report that being
on ET is not necessarily associated with weight gain in
postmenopausal BC survivors; in fact, a majority of sur-
vivors in our sample (61%) maintained their weight or lost
weight within this timeframe. However, 39% of the women
in our sample did gain[2 kg during the first 2 years of ET.
Table 2 continued
Weight status after 2 years on endocrine treatment (ET) p value
[2 kg weight loss
(N = 81, 27%)
Stable weight
(N = 102, 34%)
[2 kg weight gain
(N = 117, 39%)
Surgery
Lumpectomy (N = 169) 32.5% 35.5% 32% <0.01
Mastectomy (N = 128) 20% 32% 48%
Axillary surgery
Axillary dissection (N = 92) 12% 33% 55% <0.01
Sentinel biopsy (N = 190) 34% 33% 33%
Chemotherapy
None (N = 152) 36% 38% 27% <0.01
Neoadjuvant (N = 76) 8% 30% 62%
Adjuvant (N = 72) 29% 31% 40%
Radiation
Yes (N = 203) 26% 33% 41% 0.46
No (N = 97) 30% 36% 34%
Endocrine treatment (ET)
Tamoxifen only (N = 43) 23% 42% 35% 0.16
Exemestane only (N = 8) 38% 0% 63%
Anastrozole only (N = 113) 32% 32% 36%
Letrozole only (N = 57) 18% 37% 46%
More than one AI (N = 40) 23% 28% 50%
Tamoxifen and AI (N = 39) 33% 41% 26%
Time from breast cancer diagnosis to start of ET (years) 0.41 0.44 0.50 0.13
Values in bold are statistically significant
BMI body mass index, kg kilograms, SD standard deviation, HER 2 human epidermal growth factor receptor 2, AI aromatase inhibitor
the data were gathered or shortly thereafter; no data were
entered on a recall basis. For our study, diagnosis and
treatment data were cross-checked throughout a patient’s
record to reduce the possibility of data misclassification.
Variables analyzed in our study were for the same purposes
as they were entered into the EMR; no new variables were
implied or calculated. A further advantage of EMR data is
the collection of weight data over time that was indepen-
dently assessed by nursing staff using standardized clinic
procedures, rather than self-reported weight. We did not
have independent verification of ET adherence; however,
evidence in clinician notes of ET non-adherence or dis-
continuation was a criterion for exclusion from the study.
Fig. 1 Histogram of weight
change (2 kg increments)













Normal BMI Overweight Obese I Obese II
>2kg wt loss within 2kg loss/gain >2kg wt gain
Fig. 2 Participants grouped by
Body Mass Index at breast
cancer diagnosis and weight
change during endocrine
treatment (%)
We found no differences in weight trajectories among the 
different ETs (tamoxifen and various AIs). Weight gain 
was primarily associated with higher disease stage and 
more intense treatment, with higher proportions of weight 
gain seen in women diagnosed with Stage II or III, PR-
positive or HER2-positive tumor, having a mastectomy, 
undergoing axillary node dissection, receiving chemother-
apy, and especially receiving neoadjuvant chemotherapy.
The use of EMR data for our retrospective cohort study 
had several advantages. One is the accuracy and details 
available in oncology provider and other clinical personnel 
notes describing BC diagnosis and treatment. Data were 
entered by clinical personnel into the EMR at the moment
Table 3 Relative risk for gaining[2 kg versus not gaining[2 kg (stable weight or weight loss)
Variable Relative risk (95% CI) p value
Age at diagnosis 0.98 (0.96, 0.99) 0.002
Race
Other (N = 73) Ref
White (N = 227) 1.31 (0.91, 1.91) 0.15
Marital status
Other (N = 95) Ref
Married (N = 167) 1.48 (1.04, 2.12) 0.03
Currently employed
No (N = 136) Ref
Yes (N = 11) 0.97 (0.72, 1.32) 0.85
BMI at diagnosis
Normal (18.5 to\25) (N = 94) Ref
Overweight (25 to\30) (N = 80) 1.21 (0.83, 1.76) 0.32
Obese I (30 to\35) (N = 59) 1.21 (0.80, 1.81) 0.36
Obese II (C35) (N = 52) 1.10 (0.71, 1.70) 0.68
Weight change (kg) between diagnosis and start of ET 0.98 (0.97, 0.99) <0.0001
Weight at start of ET 1.00 (0.99, 1.00) 0.36
Hormone replacement therapy
Yes (N = 117) 1.05 (0.73, 1.50) 0.81
No (N = 89) Ref
Total number of comorbidities
0–1 comorbidities (N = 103) Ref
2–3 comorbidities (N = 138) 1.03 (0.75, 1.41) 0.87
C4 comorbidities (N = 59) 0.96 (0.64, 1.45) 0.85
Stage
Stage 0 (N = 5) 0.67 (0.11, 3.94) 0.66
Stage I (N = 127) Ref
Stage II (N = 108) 1.42 (1.01, 2.01) 0.04
Stage III (N = 52) 1.99 (1.41, 2.82) 0.0001
Grade
1 (N = 77) Ref
2 (N = 124) 1.10 (0.76, 1.61) 0.61
3 (N = 83) 1.20 (0.81, 1.78) 0.36
Estrogen receptor
Positive (N = 294) 0.97 (0.33, 2.86) 0.96
Negative (N = 5) Ref
Progesterone receptor
Positive (N = 248) 0.70 (0.51, 0.96) 0.03
Negative (N = 48) Ref
HER2
Positive (N = 35) 1.51 (1.07, 2.13) 0.02
Negative (N = 250) Ref
Surgery
Lumpectomy (N = 169) Ref
Mastectomy (N = 128) 1.49 (1.12, 1.98) 0.006
Axillary surgery
Axillary dissection (N = (92) 1.67 (1.27, 2.20) 0.0002
Sentinel biopsy (N = 190) Ref
black women from our study due to BC recurrence or
metastasis within the first years since BC diagnosis. With
regard to postmenopausal women, non-Hispanic black
women age 50 and above are more likely to have HR-
negative tumors compared to all other racial and ethnic
groups [67]. Thus, we believe our sample is generalizable
to the overall population of postmenopausal BC survivors
with early-stage hormone receptor-positive tumors.
Our study contributes to the literature pertaining to
weight gain in BC survivors and specifically to the very
limited literature pertaining to weight change during ET.
We identified only one other study in which the sample
consisted primarily of postmenopausal BC survivors,
which reported 2–5 kg weight gain within the first year in
27% of women on anastrozole and 27% of women on
tamoxifen [58]. Further studies are needed to compare
different types of ET within a larger sample of BC sur-
vivors and to investigate the myriad additional factors that
may contribute to clinically significant weight gain in
survivorship. It is important that future studies focus on
longitudinal weight trajectories with clearly stated start and
end dates, to facilitate comparisons of findings across
studies. It is also important for future studies to include
amount of weight change in kilograms or pounds, and
describe patient characteristics associated with weight gain
loss or stable weight rather than just mean weight change.
While it is reassuring that a majority of the post-
menopausal BC survivors in our sample did not gain[2 kg
during ET, a sizeable proportion did gain weight. The
associations with disease severity and related treatment that
Table 3 continued
Variable Relative risk (95% CI) p value
Chemotherapy
None (N = 152) Ref
Neoadjuvant (N = 76) 2.29 (1.67, 3.14) <0.0001
Adjuvant (N = 72) 1.49 (1.02, 2.19) 0.04
Radiation
Yes (N = 203) 1.22 (0.88, 1.68) 0.23
No (N = 97) Ref
Endocrine treatment (ET)
Tamoxifen only (N = 43) Ref
Exemestane only (N = 8) 1.79 (0.91, 3.52) 0.09
Anastrozole only (N = 113) 1.04 (0.65, 1.67) 0.87
Letrozole only (N = 57) 1.31 (0.80, 2.15) 0.29
More than one AI (N = 40) 1.43 (0.86, 2.39) 0.17
Tamoxifen and AI (N = 39) 0.74 (0.38, 1.44) 0.37
Time from breast cancer diagnosis to start of ET 0.22 (0.01, 0.43) 0.04
Relative risks in bold are statistically significant
And, the first 2 years of ET are a time period when ET 
adherence and continuation as prescribed are among the 
topics for provider–patient discussions during routinely 
scheduled clinic visits.
An important limitation of our study is that the EMR 
used in our study did not include high-quality data on other 
factors that could affect weight trajectories, such as infor-
mation on the patient’s engagement in physical activity and 
healthy eating behavior. Our EMR also did not include 
consistent collection of data on depression, anxiety, fati-
gue, pain, and other symptoms that may directly (or indi-
rectly through reduced physical activity and/or alterations 
in eating habits) affect weight changes over time. All of 
these variables are essential for understanding weight tra-
jectories in BC survivors and in determining how to 
intervene when variables are modifiable.
White women comprised a majority of the women in our 
study; however, the proportion in our sample (76%) is in 
line with the general population of BC survivors diagnosed 
with hormone receptor-positive tumors. With regard to 
HR-positive/HER2-negative tumors, the incidence rate of 
92.7 (92.7, 92.8) in non-Hispanic white women is higher 
than the rate of 74.4 (74.2, 74.6) in non-Hispanic black 
women [32]. A study of women presenting with stage I–III 
BC similarly showed a significant difference between black 
(59.6%) as compared to white women (76.1%) with regard
to HR-positive tumors (p \ 0.001) [66]. That study also 
reported a higher proportion of high-grade tumors in black 
(64.6%) as compared to white (43.0%) women (p \ 0.001)
[66], which may have contributed to the exclusion of some
we report in our study are suggestive for oncology provi-
ders as to which survivors are most likely to gain clinically
significant weight during ET. When the BC treatment plan
is first discussed, when the ET is started, and during reg-
ularly scheduled clinic visits in the first 2 years of ET are
the time points in the cancer care continuum that present
opportunities for oncology provider–patient communica-
tion about the importance of weight management. Our own
research shows that BC patients are interested in having
timely communications about ET side effects [68] and that
it is feasible for medical oncology providers to have
communications with their patients about healthy behav-
iors such as physical activity [69]. For many women, the
BC diagnosis can be an important ‘‘teachable moment’’
[70–73] where oncology providers can impart information
and encouragement to their patients regarding healthy
behaviors that promote wellness and quality of life and,
potentially, improved prognosis and survival [74–76].
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Appendix
See Fig. 3.
N= 338 potenally eligible:
BC survivors diagnosed when they were postmenopausal, on ET for at least 2 years,
weight data in the electronic medical record from BC diagnosis through 2 years of ET
N= 5 excluded due to BC recurrence or metastasis within 2 years of ET
(as this may have independent effect on weight trajectories)
N = 6 excluded due to other non-BC cancer diagnoses and treatments and
N=2 due to other medical condions described in clinician notes as not well controlled
(as this may confound weight trajectories associated with BC treatment)
N = 3 excluded due to mobility issues
(as this may affect ability to exercise, which may have independent effect on weight trajectories)
N=24 excluded due to subopmal ET adherence or disconnuaon
(as ET dose may affect weight trajectories)
N= 300 final sample
Fig. 3 Flow diagram
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